Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.48 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28795513 | 0.85 | AGTR2 (0.43) | AGTR2NR1D1OPRM1OPRD1OPRK1 | |
| SCHEMBL28795653 | 0.82 | AGTR2 (0.45) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL22555190 | 0.82 | AGTR2 (0.46) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL4297034 | 0.82 | AGTR2 (0.46) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL6975692 | 0.82 | AGTR2 (0.46) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL4294638 | 0.81 | AGTR2 (0.46) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL6978115 | 0.81 | AGTR2 (0.46) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL22208071 | 0.80 | AGTR2 (0.44) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL22208207 | 0.79 | AGTR2 (0.43) | AGTR2 | |
| SCHEMBL6978153 | 0.75 | AGTR2 (0.41) | AGTR2NR1D1CTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-114805311-A | Spirocyclic indenes | 苏州亚盛药业有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | AGTR2 1536/4885NR1D1 2145/4885CTSL 2262/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AGTR2 1536/4885NR1D1 2145/4885CTSL 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.